Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-29

Study Completion Date

2022-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcopenia is defined by the reduction in skeletal muscle mass and physical performance. It results in a decrease in muscle strength, overall physical activity, walking and the development of balance disorders and falls. It is one of the natural consequences of aging and contributes to frailty and the appearance of geriatric syndrome (s) (Chandapasirt et al, 2015; Cruz-Jentoft et al, 2010).

Its prevalence in patients with Head \& Neck cancer is 39% (Hua et al, 2020) and is associated with an increase in postoperative complications (Achim et al, 2017; Bril et al, 2019), with greater toxicity of chemotherapy. (Wendrich et al, 2017) and reduced overall survival (Hua et al, 2020).

It is measured by CT scan (assessment of muscle volume with respect to L3 using IMAGE J software) (Teigen et al, 2018) and by clinical tests (performance tests) (Swartz et al, 2016, Cruz-Jentoft et al, 2010).

Several studies have shown a possible assessment of sarcopenia by measuring skeletal muscle mass with regard to C3 (Ufuk et al, 2019; Swartz et al, 2016).

This trial aims to evaluate the prevalence of sarcopenia in head and neck cancer evaluated by CT at C3.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies

NCT05448222

Hepatocellular Carcinoma Sarcopenia

UNKNOWN

Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy

NCT05154474

Metastatic Cancer Cancer, Breast Cancer Colon +12 more

UNKNOWN

Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT04003025

Head and Neck Squamous Cell Carcinoma

WITHDRAWN

Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients

NCT04714203

Metastatic Cancer

COMPLETED

Assessment System of Sarcopenia in Lung Cancer Patients

NCT06327594

Sarcopenia Lung Cancer Ultrasound

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Cancer of Head and Neck CT Scan

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

study population

Patient diagnosed with head \& neck carcinoma at diagnosis

sarcopenia assessment

Intervention Type OTHER

evaluation of sarcopenia by CT san at the C3 vertebrae

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sarcopenia assessment

evaluation of sarcopenia by CT san at the C3 vertebrae

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient over 18 years old,
* affiliated to the social security scheme,
* suffering from locally advanced head \& neck cancer (stages I to IVB) at diagnosis,
* not operable,
* justifying treatment by radiotherapy, whether or not associated with chemotherapy or targeted therapy (eg: monoclonal antibodies, immunotherapy) whatever the proposed modalities.

Exclusion Criteria

* patient treated by non-conservative surgery and cervical lymph node dissection making it impossible to assess muscle mass with regard to C3,
* metastatic disease,
* minor patient,
* adult patient under guardianship,
* pregnancy or breastfeeding in progress.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No